Latest Articlesddd
About the CRISPR/Cas9 Gene Editing Patent Shareholders of biotechnology firms specialized in CRISPR gene editing technology …
Immunomedics (IMMU) and Seattle Genetics (SGEN) announced an exclusive global licensing agreement enabling Seattle Genetics to …
Incyte (INCY) and Agenus (AGEN) announced an amendment of the License, Development and Commercialization Agreement that …
The FDA’s Center for Drug Evaluation and Research (CDER) informed Portola (PTLA) that it does not …
Gilead Sciences (GILD) was subjected to what we believe is an exaggerated stock selloff following the …
Prohost Letter #404 Part 2 Synthetic Biology (2) A Brief History DNA is the software of …
XOMA Establishes Proof-of-Concept for 358 in Congenital Hyperinsulinism and Hypoglycemia Post-Bariatric Surgery Congenital Hyperinsulinism Phase 2 …
It seems that the global Takeda (TKPYY) has guessed well what it should pick in order …
Incyte and Calithera Biosciences Announce Global Collaboration to Develop and Commercialize CB-1158, a Small Molecule Arginase Inhibitor …
Prohost Letter #404 Part 1 HAPPY SPIRITUAL HOLIDAYS HAPPY NEW YEA
Today, Jounce Therapeutics has begun trading on the NASDAQ under the ticker symbol (JNCE). The Company, …
A few months ago, we heard news that a Belgium firm called Celyad (CYAD) has concluded …
Vertex (VRTX) entered into a licensing agreement with Merck KGaA, Darmstadt, Germany for the worldwide development …
Amgen (AMGN) The Journal of the American Medical Association (JAMA) published findings from three Phase 3 …
ARIAD Pharmaceuticals’ (ARIA) stock jumped 75% today. The oncology firm entered into a definitive agreement to be …
Extremely important, not just exciting, were the results of Halozyme Therapeutics’s (HALO) Phase 2 randomized, multi-center …
GILEAD (GILD) One analyst who aimed at bringing only the negatives about biotech has finally succeeded …
Hi and Happy New Year 2017 In a couple of days, you will receive the NEW …
MANUFACTURING ISSUES?! Why PORTOLA Stock Rallied? On Aug. 17, 2016, we learned that the FDA sent …
Observing the biotech sector’s stock prices post losses yesterday, Wednesday, Dec. 21 convinced us that investors …
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. Accept Privacy policy
